What is GYRE's Value Score?

Gyre Therapeutics, Inc. - Common Stock (GYRE) has a StockPik Value Score of 52 out of 100 — a mid-range score, indicating moderate value characteristics. The Value Score is a composite ranking built from P/E ratio, P/B ratio, Graham Number, ROE, gross margin, debt-to-equity, current ratio, and Piotroski F-Score, calculated from SEC EDGAR annual filing data.

What is GYRE's Piotroski F-Score?

Gyre Therapeutics, Inc. - Common Stock (GYRE) has a Piotroski F-Score of 3 out of 9 — a weak score indicating financial deterioration across multiple criteria. The F-Score assesses nine binary financial criteria across profitability, leverage, and operating efficiency. A score of 7–9 indicates a financially improving company; a score of 0–3 is a warning sign.

Is GYRE trading below its Graham Number?

GYRE is currently trading above its Graham Number. The stock price of $6.91 exceeds the Graham Number of $1.05, meaning it does not meet Graham's criterion for a margin of safety at the current price. The Graham Number is calculated as √(22.5 × EPS × Book Value Per Share) and represents Benjamin Graham's ceiling price for a defensive investor.

What is GYRE's Graham Number?

GYRE's Graham Number is $1.05, calculated using the Benjamin Graham formula √(22.5 × EPS × Book Value per Share). The Graham Number is an estimate of intrinsic value — the maximum price a defensive investor should pay. At the current price of $6.91, GYRE is trading 558% above its Graham Number.

What is GYRE's Piotroski F-Score?

GYRE's Piotroski F-Score is 3 out of 9, indicating weak financial health and possible deterioration. The Piotroski F-Score evaluates nine criteria across profitability, leverage, and operating efficiency. Scores of 7 or above are considered strong; 3 or below indicate financial weakness.

Is GYRE (Gyre Therapeutics, Inc. - Common Stock) undervalued?

GYRE scores 52/100 on StockPik's Value Score, an above-average rating. The stock trades 558% above its Graham Number of $1.05.

What is GYRE's P/E ratio?

GYRE's trailing P/E ratio is 483.2x — an elevated earnings multiple, potentially pricing in high growth expectations. The Healthcare sector average P/E is 25.2x. Compare against other Healthcare stocks in the StockPik screener.

What sector is Gyre Therapeutics, Inc. - Common Stock (GYRE) in?

Gyre Therapeutics, Inc. - Common Stock (GYRE) is in the Healthcare sector, specifically in the Pharmaceutical Preparations industry. Compare it against other Healthcare stocks by Value Score, P/E ratio, and Piotroski F-Score on StockPik.

Back to Screener

Gyre Therapeutics, Inc. - Common Stock (GYRE)

NASDAQ Small Cap

Healthcare › Pharmaceutical Preparations

$6.91

Market Cap: $771M

Data as of Jun 30, 2026 (TTM)

Price History

Feb 9, 2026 — Aug 24, 2026

Investment Snapshot

Trading 558% above Graham Number — above intrinsic value estimate
Piotroski F-Score 3/9 — signs of financial weakness
Loss-making — negative ROE of -73.9%
Revenue growing at 10% annually

Gyre Therapeutics, Inc. - Common Stock (GYRE) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $771 million . Key value metrics: P/E ratio 483.2, P/B ratio 7.79, Piotroski F-Score 3 out of 9 .

Value Score

out of 100

Try PRO Free — See Full Breakdown

Key Metrics

P/E Ratio

483.22

P/B Ratio

7.79

EPS

$-0.15

Div. Yield

—

PEG Ratio

—

P/S Ratio

—

EV/EBITDA

—

ROE

—

ROA

—

Gross Margin

—

Op. Margin

—

Net Margin

—

Debt/Equity

—

Current Ratio

—

Unlock 19 More Metrics — 7 Days Free

Current vs 5-Year Average

Based on 5 years of SEC filings

Net Margin

—

↑ +2.1pp avg —

Gross Margin

—

↑ +2.1pp avg —

Operating Margin

—

↑ +2.1pp avg —

Return on Equity

—

↑ +2.1pp avg —

Debt / Equity

—

↑ +2.1pp avg —

See How Margins & ROE Have Trended — Try PRO

Revenue & Net Income

Profit Margins

Track Gross, Operating & Net Margins — Try PRO

EPS & Free Cash Flow Per Share

See EPS & Free Cash Flow Trends — Try PRO

Financial Statements

Metric	FY22	FY23	FY24
Revenue	$X.XB	$X.XB	$X.XB
Gross Profit	$X.XB	$X.XB	$X.XB
Operating Income	$X.XB	$X.XB	$X.XB
Net Income	$X.XB	$X.XB	$X.XB
EBITDA	$X.XB	$X.XB	$X.XB
Total Assets	$X.XB	$X.XB	$X.XB
Total Liabilities	$X.XB	$X.XB	$X.XB

Unlock 5 Years of Financials — Start Free Trial

Data sourced from SEC EDGAR and Polygon.io. Methodology. View more Healthcare stocks →

Gyre Therapeutics, Inc. - Common Stock — Fundamental Analysis Summary

Gyre Therapeutics, Inc. - Common Stock (GYRE) is currently trading 558% above its Graham Number of $1.05, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 483.2x.

On financial health, GYRE shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and negative return on equity of -73.9% (sector average: -20.1%), and minimal leverage with a debt-to-equity ratio of 0.22.

StockPik's composite Value Score for GYRE is 52/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.

GYRE reports a high gross margin of 92.0% (sector average: 37.4%) and a negative operating margin of -13.4%.

GYRE shows revenue growing at 10% year-over-year, with earnings declining at 45%.

Top Value Stocks in Healthcare

Symbol	Name	Price	P/E	Score
CGEN	Compugen Ltd. - Ordinary Shares	$2.28	6.1	100
ABEO	Abeona Therapeutics Inc. - Common Stock	$5.99	5.2	100
GMAB	Genmab A/S - American Depositary Shares	$33.45	2.2	100
EMBC	Embecta Corp. - Common Stock	$3.29	1.7	100
CRMD	CorMedix Inc. - Common Stock	$8.75	3.5	100

Browse all Healthcare value stocks →

How is the Value Score calculated?

Read our full methodology →

How is the Graham Number calculated?

Benjamin Graham's intrinsic value formula, worked examples, and how to use it →

GXO — GXO Logistics, Inc. Common Stock

Hyatt Hotels Corporation Class A Common Stock — H